The IPO Buzz: Attovia Prices Upsized IPO at $17 – Top – & Stock Up 29 Percent in NASDAQ Debut
Attovia Therapeutics (ATTO), a Phase 1 biotech developing drugs to treat chronic itching and IBD, priced its IPO at $17.00 – the top of its range, as expected – and sold 17 million shares – matching the IPO’s upsized terms disclosed this morning – to raise $289 million on Tuesday night, Aug. 4, 2026. At pricing, […]
August 4, 2026 Read More